Etonogestrel - Contraindications
These conditions, allergies, and situations mean Etonogestrel should NOT be used. From the US FDA-approved drug label Section 4.
4 CONTRAINDICATIONS NuvaRing is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases.
Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions ] Have cerebrovascular disease [see Warnings and Precautions ] Have coronary artery disease [see Warnings and Precautions ] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions ] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions ] Have uncontrolled hypertension [see Warnings and Precautions ] Have diabetes mellitus with vascular disease [see Warnings and Precautions ] Have headaches with focal neurological symptoms or migraine headaches with aura [see Warnings and Precautions ] Women over age 35 with any migraine headaches [see Warnings and Precautions ] Liver tumors, benign or malignant or liver disease [see Warnings and Precautions and Use in Specific Populations ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions ] Pregnancy, because there is no reason to use CHCs during pregnancy [see Use in Specific Populations ] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings and Precautions ] Hypersensitivity reactions, including anaphylaxis and angioedema, to any of the components of NuvaRing [see Warnings and Precautions and Adverse Reactions ] Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions and Drug Interactions ] A high risk of arterial or venous thrombotic diseases Breast cancer Liver tumors or liver disease Undiagnosed abnormal uterine bleeding Pregnancy Hypersensitivity, including anaphylaxis and angioedema, to any of the components of NuvaRing Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir